We work with over 30 biotechnology, pharmaceutical and veterinary companies as well as research centres and universities around the world to help them complete their R&D processes more quickly and economically
. This means that we can get new medicines to treat cancer, Alzheimer's, diabetes and a variety of rare diseases, among others, to patients faster.
With our SaaS platform, which we expand regularly with new programs and applications, researchers can easily predict biological activities, expand libraries (virtual screening), and understand why compounds work or how they bond with proteins, in addition to other applications. This helps cut the cost and time of the different phases of drug development. In developing the SaaS platform, we apply machine learning and big data
techniques in order to speed up and improve the results and cut the time-to-market for new drugs
We are Amazon Web Services
technology partners (a seal of quality that has only been awarded to five companies in this sector) and members of the Microsoft BizSpark Plus
Mind the Byte was founded in 2011 by Alfons Nonell-Canals
, who holds a PhD in Computational Chemistry and is a specialist in computer-aided drug design, in the development of software to modify active compounds, and in large-scale chemical and biological analyses. His motivation for founding the company was his desire to ensure that everyone has access to the medications they need
We've taken part in several excellence programmes, including the AWS Start-up Challenge, BioEmprenedorXXI, TEA by ACCIÓ and IESE, and Start-Up Catalonia.
We are technology partner of Amazon Web Services (AWS):